To evaluate the therapeutic effect of Vemurafenib on necroptosis-associated diseases in vivo, we utilized the TNFα-induced systemic inflammatory response syndrome (SIRS) mice model (Fig. 6A), which is a RIPK kinase-driven disease and strongly prevented by inhibiting necroptotic pathway [2]. Here, TNF is linked to systemic inflammatory response syndrome.